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INTRODUCTION
Colorectal cancer (CRC) is the second of the fourth 
most common cancer in industrialized countries,  leading 
to mortality. In Ukraine, the incidence of malignant tu­
mors of colon is 28.3 per 100,000 males, rectum and 
anus is 27.2 per 100,000 males; the incidence of malig­
nant tumors is 19.7 per 100,000 females and is 15.1 per 
100,000 females, respectively. Worldwide incidence 
of malignant tumors of the colon, rectum and anus is 
16.2 per 100,000 males, and is 15.9 per 100,000 males, re­
spectively, and is 11.8 per 100,000 females and is 9.2 per 
100,000 females, respectively, and is significantly lower 
than in Ukraine [1]. In Europe (in Germany and Nor­
way), the highest incidence rate of CRC among men is 
43–59 per 100,000 individuals and among women is 27–
37 per 100,000 individuals per year and approximate­
ly correspond to the number of patients in the USA [2]. 
Mortality in patients with colon cancer is 41.8% and for 
rectal cancer is 32.9%. Almost half of patients dies in 
the first year after diagnosis confirmed. The incidence 
of CRC increases after 50 years to 160 or more cases per 
100,000 people, and at the age over 60 years it  increases 
to 259 cases [3]. In Ukraine, 15,000–17,000 new ca ses of 
CRC are diagnosed annually. The highest mortality rate 
was observed in the age group of individuals over 60 years 
(56–60%) [4]. In patients with hereditary CRC the mani­
festation of the disease is characterized by a younger age, 
a high penetrance of the disease, the preva lence of tumors 
with low differentiation, appe arance of metastases both 
before treatment and after surgery and lower rate of three­
years survival [5]. The etiologies of the rema ining 20–
30% of inherited CRCs are not completely understood. 
According to the literature data the diseases with  highest 
risk of CRC includes hereditary polyposis syndromes, 
most often familial ade nomatous polypo sis (FAP), Lynch 
syndrome and inflammatory bowel dise ase [6]. In pa­
tients with FAP the risk of CRC occurrence is approach 
to 100%, and in patients with Lynch syndrome the risk 
of CRC is less and accounts to 50–70%. Approximate­
ly 25% of patients with colorectal phenotypes indistin­
guishable from FAP and its attenua ted form — AFAP, 
can be associated with biallelic inherited mutations of 
BER (base excision repair) gene,  MUTYH (human MutY 
homolog) in the absence of demonstrable inherited mu­
tations of APC gene. The established role of MUTYH is 
BER of adenine residues that have been misincorporated 
opposite guanine or 8­oxoG [7]. In 60–70% of patients 
with MUTYH­associated polyposis (MAP) CRC diag­
nosed at an average age of 47 years [8]. The risk of CRC 
in patients with Lynch syndrome younger than 45 years 
increases in 3 times in comparison to the general popu­
lation rate [9].
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It is known that 10–15% of deaths from the inflam­
matory bowel disease — ulcerative colitis and Crohn’s 
disease, caused by CRC. Patients with cancer associa­
ted with ulcerative colitis at 10–15 years younger com­
pared with patients with sporadic CRC, and for terms 
of 5­year survival the difference between the two groups 
were didn’t observed [10].
The aim of this research is to analyze the distribution 
of males and females by the age of CRC onset with and 
without hereditary predisposition to the disease to iden­
tify individuals at risk group.
SUBJECTS AND METHODS
During the 2002–2014 years it was analyzed the medi­
cal records and genealogical information in 182 patients 
with CRC, including 94 males and 88 females. The diag­
nosis was established using clinical, endoscopic, radio­
logical and laboratory methods. All diagnoses were mor­
phologically confirmed. Patients were residents of the six 
regions of Ukraine: Lviv, Ivano­Frankivsk, Ternopil, Vo­
lyn, Vinnytsia and Zakarpattya. The collection of gene­
alogical information in 3–4 generations was carried out 
using a single registration of probands according to the 
appropriate ethical requirements. The mode of inheri­
tance of the diseases was determined using clinical, ge­
nealogical, laboratory and literature (OMIM) database. 
The age of CRC onset in cases with familial anamnesis 
of cancer was evaluated in the probands only and does 
not take into account the age manifestation of the dise­
ase in their relatives. Selection of patients in the group of 
high risk of Lynch syndrome was performed  according 
to 1–3 Amsterdam diagnostic criteria.
«Positive» familial anamnesis for CRC was confirmed 
in 61 patients. Its including cases, when recurrence of 
cancer within the family in one or more of first degree 
relatives and in subsequent generations, was established. 
Of these, 40 patients (15 males and 25 females) to met 
1–2 of Amsterdam criteria for Lynch syndrome, 9 pa­
tients to met 3 Amsterdam criteria, and thus confirmed 
Lynch syndrome (4 males and 5 females). Only 1 patient 
of these group had Lynch syndrome I and other patients 
have Lynch syndrome II. The selection of the group of 
patients with Lynch syndrome I was carried out consi­
dering accordance Amsterdam I diagnostic criteria that 
includes three basic requirements:
•	 onset of CRC in at the least 3 individuals span­
ning two generations (FAP should be excluded);
•	 at least one of these individuals is the first­degree 
rela tive of the other two;
•	 at least one of the individuals must have a diag­
nosis prior to age 50 years [11].
Selection of patients in the risk group of Lynch syn­
drome II carried out with regarding supplemented, i.e. 
Amsterdam II criteria. Requirements include, in fulfilled 
to the same 3 diagnostic criteria I, some additions: Lynch 
syndrome II should be suspected in probands and their 
relatives with CRC/or extracolonic cancers (endometri­
al, hepatobiliary system, stomach, small intestine, skin, 
genitourinary cancer) [12]. In 1997, the Natio nal Can­
cer Institute published a set of recommendations called 
the Bethesda guidelines for the identification of individu­
als with synchronous or metachronous tumors who 
should receive genetic testing for Lynch syndrome rela­
ted tumors. Of Bethesda criteria we considered only item 
requirements for the presence of synchronous or meta­
chronous CRC without the genetic testing for microsa­
tellite instability. Proof of Lynch syndrome I and II are 
three compliance Amsterdam I and II diagnostic criteria. 
Fulfilled with one or two criteria is regarded as a famili­
al cancer of different etiology. 8 patients with «positive» 
familial anamnesis for CRC did not fulfill the Amster­
dam criteria, had multiple adenomatous polyposis and 
CRC. Of these 7 patients (2 males, 5 females) were di­
agnosed FAP and one male had MAP. One female had 
hamartomatous polyposis — Peutz — Jeghers syndrome. 
The remaining three patients had familial CRC­associ­
ated inflammatory bowel diseases: 2 males had Crohn’s 
disease, and 1 male had ulcerative colitis. The diagnosis 
of adenomatous polyposis (FAP, MAP) and hamarto­
matous polyposis (Peutz — Jeghers syndrome) was con­
firmed using clinical, endoscopic diagnostic criteria, ge­
nealogical information and molecular genetic analysis re­
sults. The molecular genetic analysis of the DNA samples 
of leucocytes of peripheral blood was carried out in the 
Institute of Human Genetics of the Polish Academy of 
Sciences (Poznan) on the basis of scientific cooperation.
Statistical analysis was performed using standard 
methods [13]. The distribution of the obtained data and 
its compliance with the predicted theoretical distribution 
was evaluated using Pearson’s chi­squared test (χ2). Veri­
fication of statistical hypotheses performed at p ≤ 0.05. 
For the statistical analysis of genetic data «GenePop» 
used the computer program, available online (http://
wbiomed.curtin.edu.au/genepop).
RESULTS AND DISCUSSION
Patients with CRC were symbolically divided into two 
groups regarding patient’s familial history of the dise­
ase: without familial anamnesis for the disease were 121 
(66.5%) patients (group 1) and with hereditary predispo­
sition for the disease were 61 (33.5%) patients (group 2) 
(Table 1).
Table 1
The distribution of males and females with CRC for groups without/
with hereditary predisposition to the disease
Patient’s 
gender 
(number of 
patients)
CRC patients without 
family history to the 
disease (group 1), 
absolute number (%) 
CRC patients with family 
history to the disease 
(group 2), 
absolute number (%)
Males
(n = 94)
69 (57) 25 (41)
Females
(n = 88)
52 (43) 36 (59)
Total 121 (100) 61 (100)
The I stage of tumor process was identified in 7 (5.8%) 
patients, the II stage were in 81 (67.0%) patients, the 
III stage were in 23 (19.0%) patients, and the IV stage 
were in 10 (8.2%) patients of the total number of patients 
without family history of CRC. Among patients with he­
reditary predisposition for CRC the I stage of tumor pro­
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cess were diagnosed in 3 (4.9%) patients, the II stage were 
in 34 (55.7%), the III stage were in 14 (23.0%) and the 
IV stage were in 10 (16.4%) patients (Table 2).
Table 2
The distribution of CRC patients depending of the stages of tu-
mors process in the groups of individuals without/with family histo-
ry to the disease
The stages of 
CRC
CRC patients without 
family history to the 
disease (group 1), 
absolute number (%)
CRC patients with family 
history to the disease 
(group 2),
absolute number (%)
I 7 (5.8) 3 (4.9)
II 81 (67.0) 34 (55.7)
III 23 (19.0) 14 (23.0)
IV 10 (8.2) 10 (16.4)
Total 121 (100) 61 (100)
Earlier tumor stages (I + II) were diagnosed in 88 
(72.7%) patients of the group 1 and later tumor sta ges 
(III + IV) have 33 (27.3%) individuals, compared to 
the number patients of the group 2 — 37 (60,6%) and 
24 (39.4%) patients, respectively. Thus, in patients with 
a family history of CRC were diagnosed more advanced 
forms of the disease.
The distribution of males and females by the age of 
CRC onset is shown on Fig. 1.
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Fig. 1. The distribution of males and females by age manifes­
tation for the CRC
Age manifestation of the disease was varied in relation 
of patient’s gender. The largest number of males was ob­
served at the age from 65 to 74 years, which were on 15–
20 years later than females. Females were ill at an earli­
er age starting from 25 years. At the age of 25–29 years 
were observed 3 (3.4%) females with CRC unlike male 
patients — 2 (2.1%) were registrated starting at the age 
of 35–39 years. The number of female patients at the age 
of 35–39 years and of 40–44 years were 5 (5.6%) and 
6 (6.8%) individuals, respectively, exceeded in twice the 
number of male patients at the same age — 2 (2.1%) and 
3 (3.2%) individuals, respectively. The incidence of CRC 
in males at the age of 70–74 years was twice higher, than 
in females: 19 (20.2%) male patients and 9 (10.2%) fe­
male patients, respectively. According to the data of Bul­
letin of the National Cancer Registry in Ukraine, the fre­
quency of females at the age of 25–29 years with cancer 
of the colon and rectum was higher (1.8/100,000), than 
males (0.8/100,000), but at the age of 80–84 years the 
frequency of cancer of the same localization was higher in 
males (109.8/100,000), than females (22.1/100,000) [1]. 
The number of male patients aged over 80 years was ex­
ceeded the number of female patients: 9 (9.6%) males 
and 5 (5.7%) females. Wider range age (25–86 years) of 
CRC onset was observed in females, unlike males (35–
82 years). The incidence of CRC after 80 years in females 
decreased to the level of the age group of 30–39 years 
unlike males: 5 (5.7%) females and 9 (9.6%) males. Ac­
cording to the literature data sporadic colon cancer pro­
gresses stepwise from adenoma to carcinoma, with a la­
tency period that may last decades and with highest in­
cidence during advancing age [14], it is conceivable that 
tumors start developing slowly before menopause, but 
rapidly progress with cessation of ovarian estrogen pro­
duction [14, 15]. In the observed group 8 (9.1%) female 
patients at the age range of 45–49 years were found, and 
the maximum number — 14 (15.9%) females, were found 
at the age of 50–54 years. A stable high level of CRC in­
cidence (10.0–11.0% of females) was observed in patients 
at 55–74 years. It was known that antiproliferative effects 
of 17β­estradiol are mediated through the estrogen re­
ceptor (ER)­β, which is the predominant ER subtype in 
the human colon mucosa [16]. In addition, there is evi­
dence to suggest that the chemopreventive effect of es­
trogen against CRC is mediated in part through vitamin D 
receptor (VDR)­activated antiproliferative intracellular 
signaling. Early during tumor progression human colo­
nocytes express high levels of the CYP27B1­encoded 
25­hydroxyvitamin D­1α­hydroxylase, the enzyme that 
synthesizes the active vitamin D metabolite, 1,25­dihy­
doxyvitamin D3 (1,25 (OH)2D3), which when bound to 
its cognate receptor, the VDR, effectively inhibits pro­
liferation and promotes differentiation in human colon 
cancer cells [17]. Estrogens have been shown to increase 
VDR and CYP27B1 expression and activity in human 
colonocytes. Thus, activation of ER­β causes antitumor 
effect. Estrogens increase the potential antiproliferative 
effect of vitamin D hormone [17–21]. However,  women 
are protected from more aggressive cancer in the colon 
though not in the rectum until well after menopause. This 
likely reflects the differential sensitivity of the mucosa at 
these sites against the anticancer effects triggered by ac­
tivation of ER­β [22].
The manifestation of the disease occurred in females 
at a younger age, ranging from 25 years, that is on 11 years 
earlier, than in males. The maximum number of men — 
6 (24.0%) patients was observed at the age range of 65–
69 years that more than twice exceeded the number of 
women — 4 (11.0%) patients. The number of patients 
of both genders in older age (over 75 years) was lower 
(5.6%), than in patients without family history (6.8%, 
see Fig. 1). The male patients at this age range (Fig. 2) 
never found inlike to male patients without the family 
history of CRC (6.4%, see Fig. 1).
In probands with «positive» familial anamnesis the 
peak age of the disease manifestation was lower by 5 years 
for both genders: in males is 65–69 years, and in females 
is 45–49 years, compared with age of individuals with­
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out family history (in men is 70–74 years and in women 
is 50–54 years). The analysis of distribution on age and 
gender of CRC onset in probands with «positive» fami­
lial anamnesis for CRC, is shown on Fig. 2.
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Fig. 2. The distribution of males and females by age mani­
festation for the CRC with familial anamnesis for the disease
Among the 182 probands «positive» familial anam­
nesis was found in 61 (33.5%) patients: in 25 males and 
36 females. In 7 (11.5%) relatives of probands the dise­
ase repeated in three generations. Recurrence of CRC in 
2–3 generations of families allows to confirms an auto­
somal dominant mode of inheritance of the disease in 
some patients. The frequency of various diseases of co­
lon, associated with CRC and family history of this dise­
ase, is shown in Fig. 3.
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Fig. 3. The frequency of various diseases of colon, associated 
with CRC, and «positive» familial anamnesis of this disease: 
1 — familial CRC (patients to met 1–2 of Amsterdam crite­
ria for Lynch syndrome) — 65.6%; 2 — Lynch syndrome — 
14.8%; 3 — FAP — 11.5%; 4 — CRC­associated inflamma­
tory bo wel diseases — 4.9%; 5 — MAP — 1.6%; 6 — Peutz — 
Jeghers syndrome — 1.6%
It was determined (see Fig. 2) that among patients 
with family history of CRC 18 (29.5%) individuals had 
monogenic diseases of colon, such as: Lynch syndrome — 
9 (14.8%), FAP — 7 (11.5%), MAP — 1 (1.6%) and 
Peutz — Jeghers syndrome — 1 (1.6%). Among them 
were 7 males and 11 females. Inflammatory bowel dise­
ase ulcerative colitis and Crohn’s disease, associated 
with CRC, was found in 3 (4.9%) patients with heredi­
tary predisposition to CRC. The familial cancer was the 
most common in this group of probands and was diag­
nosed in 40 (65.6%) patients. According to the literature 
data, of common malignancies, CRC has one of the lar­
gest proportions of familial cases. Kindred and twin stu­
dies estimated that approximately 30% of all CRC cases 
are an inherited form of the disease [23]. It is known that 
in Lynch syndrome patients there is a different lifetime 
risk and earlier age of manifestation for CRC — especial­
ly in MSH6 mutation carriers, in men and women [24].
In 25 (41.0%) males and in 36 (59.0%) females «posi­
tive» familial anamnesis for CRC was confirmed (p > 0.05). 
It was observed 69 (57.0%) males and 52 (43.0%) females 
without family history of CRC (p > 0.05). Despite the 
lack of a statistically significant difference between the 
groups of males and females, probably due to the small 
number of patients in groups, the distribution of cancer 
cases in the observed families demonstrates the tenden­
cy, called the Carter effect [25]. It means that the indi­
viduals of gender, which is less affected, have a higher 
hereditary predisposition compared with patients of the 
gender, which is often affected. It is known that the in­
cidence and mortality in men by 30–40% higher than in 
women, despite fluctuations depending on age [1, 24].
There was established statistically significant differen­
ce of the age of CRC onset regarding the hereditary pre­
disposition to the disease. Males and females with family 
history of CRC had lower average age of manifestation of 
the disease than in patients without a «positive» familial 
anamnesis. In male patients with family history of CRC 
the average age of the CRC onset was 50.9 ± 2.77 years 
that was approximately at 15 years less, than those with­
out family history for the disease (66.2 ± 1.10 years). In 
women with familial history of CRC the difference of 
the average age of cancer onset was 50.9 ± 2.91 years less 
more than 9 years, than those without a genetic predis­
position to the disease — 60.2 ± 1.72 years (Table 3).
Table 3
Gender differences of average age of CRC onset and hereditary 
predisposition to this disease
Gender Family history of CRC
Average age of CRC 
onset (in years),
М ± m
р
Males 
(n = 94)
n1= 69 − 66.2 ± 1.10 <0.001
n2 = 25 + 50.9 ± 2.77
Females 
(n = 88) 
n1 = 52 − 60.2 ± 1.72 <0.01
n2 = 36 + 50.9 ± 2.91
n1 — the number of patients without family history of CRC; n2 — the number 
of patients with family history of CRC.
There was not confirmed statistically significant diffe­
rence between the average age of CRC onset in patients 
of both genders with «positive» familial anamnesis of the 
disease. However, it was revealed a statistically significant 
difference (p < 0.01) for the average age of the CRC on­
set between males (66.2 ± 1.10 years) and females (60.2 
± 1.72 years) without family history.
Thus, the study of gender and age­CRC is one of 
the urgent problems of modern medicine. A precise un­
derstanding of the age of inherited CRCs manifestation 
is important for identifying at­risk individuals, impro­
ving cancer surveillance and prevention strategies, and 
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developing better diagnostic and therapeutic approa­
ches. Studies of the cases of familial and inherited colon 
cancers have led to recommendations for colon cancer 
screening. Furthermore, genetic study among this group 
of patients improves our understanding of colon cancer 
risk, pathogenesis, and prevention.
CONCLUSIONS
1. Age of the CRC onset was varied in relation of pa­
tient’s gender and hereditary predisposition to the dise­
ase. In probands with family history of CRC the peak age 
of the disease onset was 5 years lower for both genders 
(65–69 years in males and 45–49 years in females), com­
pared to the age of patients without family history (70–
74 years in males and 50–54 years in females).
2. Among probands with family history of CRC 29.5% 
individuals have monogenic cancer syndromes of co­
lon, such as: Lynch syndrome, FAP, MAP and Peutz — 
Jeghers syndrome. CRC­associated inflammatory bo­
wel disease was found in 4.9% patients with familial an­
amnesis for CRC.
3. The average age of CRC onset in probands of both 
genders with hereditary predisposition to this disease was 
the statistically significant lower, than in patients with­
out family history.
4. The statistically significant difference for the 
 ave rage age of the CRC onset between males and fe­
males without family history of the disease was revealed.
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ХАРАКТЕРИСТИКА РОЗПОДІЛУ ХВОРИХ 
НА КОЛОРЕКТАЛЬНИЙ РАК ЗА ВІКОМ 
І СТАТТЮ ЗАЛЕЖНО ВІД СПАДКОВОЇ 
ОБТЯЖЕНОСТІ ЦИМ ЗАХВОРЮВАННЯМ
М.Р. Лозинська, О.М. Федота, Л.Ю. Лозинська, 
Н.М. Прокопчук, Р.О. Піняжко
Резюме. Мета: провести аналіз розподілу хворих 
різної статі за віком маніфестації колоректально-
го раку (КРР) зі спадковою обтяженістю та без об-
тяженості цим захворюванням для виявлення осіб 
груп ризику. Об’єкт і методи: аналіз медичної до-
кументації та генеалогічної інформації у 182 хво-
рих на КРР (94 чоловіки і 88 жінок). «Позитивний» 
сімейний анамнез КРР підтверджено у 61 пробан-
да: 40 з них відповідали одному–двом Амстердам-
ським критеріям діагностики, 9 — трьом Амстер-
дамським критеріям, 7 — мали сімейний аденома-
тозний поліпоз, 3 — спадкову обтяженість на КРР, 
асоційований із запальними захворюваннями кишеч-
нику, та по одному випадку MUTYH-асоційованого 
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поліпозу і синдрому Пейтца — Єгерса. Результа-
ти: вік маніфестації захворювання варіював за-
лежно від статі пацієнтів і спадкової обтяже-
ності. У пробандів із сімейним анамнезом КРР ві-
ковий пік маніфестації захворювання був меншим 
на 5 років для обох статей порівняно з віком осіб 
без спадкової обтяженості. У пробандів із КРР чо-
ловічої та жіночої статі зі спадковою обтяженіс-
тю цим захворюванням встановлено істотно мен-
ший середній вік маніфестації хвороби, ніж у хворих 
чоловіків і жінок без спадкової обтяженості. Між 
чоловіками і жінками без спадкової обтяженості 
КРР за середнім віком маніфестації хвороби вста-
новлено статистично істотну різницю. Висновок: 
встановлення віку маніфестації спадкових варіан-
тів КРР і статевих особливостей пацієнтів із цим 
захворюванням є важливим для виявлення осіб груп 
ризику, а також для покращення спостереження 
за пацієнтами із раком товстої кишки та відпра-
цювання превентивної стратегії для вдосконален-
ня діагностики і лікувальних підходів.
Ключові слова: колоректальний рак, сімейний 
анамнез, вік маніфестації хвороби, стать.
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